Molecular Diagnostics for Precision Medicine in Colorectal Cancer

Current Status and Future Perspective

Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto, Ming Tseh Lin

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Precision medicine, a concept that has recently emerged and has been widely discussed, emphasizes tailoring medical care to individuals largely based on information acquired from molecular diagnostic testing. As a vital aspect of precision cancer medicine, targeted therapy has been proven to be efficacious and less toxic for cancer treatment. Colorectal cancer (CRC) is one of the most common cancers and among the leading causes for cancer related deaths in the United States and worldwide. By far, CRC has been one of the most successful examples in the field of precision cancer medicine, applying molecular tests to guide targeted therapy. In this review, we summarize the current guidelines for anti-EGFR therapy, revisit the roles of pathologists in an era of precision cancer medicine, demonstrate the transition from traditional "one test-one drug" assays to multiplex assays, especially by using next-generation sequencing platforms in the clinical diagnostic laboratories, and discuss the future perspectives of tumor heterogeneity associated with anti-EGFR resistance and immune checkpoint blockage therapy in CRC.

Original languageEnglish (US)
Article number9850690
JournalBioMed Research International
Volume2016
DOIs
StatePublished - Jan 1 2016

Fingerprint

Precision Medicine
Molecular Pathology
Medicine
Colorectal Neoplasms
Assays
Neoplasms
Oncology
Poisons
Health care
Molecular Diagnostic Techniques
Tumors
Therapeutics
Testing
Pharmaceutical Preparations
Guidelines

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Chen, Guoli ; Yang, Zhaohai ; Eshleman, James R. ; Netto, George J. ; Lin, Ming Tseh. / Molecular Diagnostics for Precision Medicine in Colorectal Cancer : Current Status and Future Perspective. In: BioMed Research International. 2016 ; Vol. 2016.
@article{96de27951ce6402b8fd75e0b66de8e01,
title = "Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective",
abstract = "Precision medicine, a concept that has recently emerged and has been widely discussed, emphasizes tailoring medical care to individuals largely based on information acquired from molecular diagnostic testing. As a vital aspect of precision cancer medicine, targeted therapy has been proven to be efficacious and less toxic for cancer treatment. Colorectal cancer (CRC) is one of the most common cancers and among the leading causes for cancer related deaths in the United States and worldwide. By far, CRC has been one of the most successful examples in the field of precision cancer medicine, applying molecular tests to guide targeted therapy. In this review, we summarize the current guidelines for anti-EGFR therapy, revisit the roles of pathologists in an era of precision cancer medicine, demonstrate the transition from traditional {"}one test-one drug{"} assays to multiplex assays, especially by using next-generation sequencing platforms in the clinical diagnostic laboratories, and discuss the future perspectives of tumor heterogeneity associated with anti-EGFR resistance and immune checkpoint blockage therapy in CRC.",
author = "Guoli Chen and Zhaohai Yang and Eshleman, {James R.} and Netto, {George J.} and Lin, {Ming Tseh}",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/9850690",
language = "English (US)",
volume = "2016",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Molecular Diagnostics for Precision Medicine in Colorectal Cancer : Current Status and Future Perspective. / Chen, Guoli; Yang, Zhaohai; Eshleman, James R.; Netto, George J.; Lin, Ming Tseh.

In: BioMed Research International, Vol. 2016, 9850690, 01.01.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Molecular Diagnostics for Precision Medicine in Colorectal Cancer

T2 - Current Status and Future Perspective

AU - Chen, Guoli

AU - Yang, Zhaohai

AU - Eshleman, James R.

AU - Netto, George J.

AU - Lin, Ming Tseh

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Precision medicine, a concept that has recently emerged and has been widely discussed, emphasizes tailoring medical care to individuals largely based on information acquired from molecular diagnostic testing. As a vital aspect of precision cancer medicine, targeted therapy has been proven to be efficacious and less toxic for cancer treatment. Colorectal cancer (CRC) is one of the most common cancers and among the leading causes for cancer related deaths in the United States and worldwide. By far, CRC has been one of the most successful examples in the field of precision cancer medicine, applying molecular tests to guide targeted therapy. In this review, we summarize the current guidelines for anti-EGFR therapy, revisit the roles of pathologists in an era of precision cancer medicine, demonstrate the transition from traditional "one test-one drug" assays to multiplex assays, especially by using next-generation sequencing platforms in the clinical diagnostic laboratories, and discuss the future perspectives of tumor heterogeneity associated with anti-EGFR resistance and immune checkpoint blockage therapy in CRC.

AB - Precision medicine, a concept that has recently emerged and has been widely discussed, emphasizes tailoring medical care to individuals largely based on information acquired from molecular diagnostic testing. As a vital aspect of precision cancer medicine, targeted therapy has been proven to be efficacious and less toxic for cancer treatment. Colorectal cancer (CRC) is one of the most common cancers and among the leading causes for cancer related deaths in the United States and worldwide. By far, CRC has been one of the most successful examples in the field of precision cancer medicine, applying molecular tests to guide targeted therapy. In this review, we summarize the current guidelines for anti-EGFR therapy, revisit the roles of pathologists in an era of precision cancer medicine, demonstrate the transition from traditional "one test-one drug" assays to multiplex assays, especially by using next-generation sequencing platforms in the clinical diagnostic laboratories, and discuss the future perspectives of tumor heterogeneity associated with anti-EGFR resistance and immune checkpoint blockage therapy in CRC.

UR - http://www.scopus.com/inward/record.url?scp=84988691028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988691028&partnerID=8YFLogxK

U2 - 10.1155/2016/9850690

DO - 10.1155/2016/9850690

M3 - Review article

VL - 2016

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 9850690

ER -